Swiss Banks Stock News

Arctic pilot project puts dormakaba Holding (SWX:DOKA) in focus dormakaba Holding (SWX:DOKA) has started a pilot project at the Sorrisniva resort in Arctic Norway, testing its access systems in subzero conditions at the world’s northernmost ice hotel. The installation covers several parts of the resort and is intended to gather data on energy use and reliability, a development that has put the stock on some investors’ radars as they assess the business. See our latest analysis for dormakaba...

Julius Bär Gruppe recently announced major organisational and leadership changes, naming former HSBC executive Jean Nabaa as COO and creating a new Group Communications function to be led by experienced communicator Cindy Leggett-Flynn. The hires bring together deep wealth management operations expertise and high-profile crisis-tested communications experience, underscoring Julius Bär’s focus on executing its transformation agenda. Next, we examine how the appointments of Jean Nabaa and...

Sika recently expanded its reach through the acquisition of Swedish dry mortar and facade specialist Finja and a new U.S. distribution partnership with Cain & Bultman, which will carry Sika’s floor covering installation products across several southeastern states. Together, these moves highlight how Sika is building out both its Nordic manufacturing base and its North American distribution channels to serve a wider mix of professional customers. Next, we will examine how this broadened...

Key Insights Significant control over Cham Swiss Properties by retail investors implies that the general public has...

Key Insights Banque Cantonale de Genève's significant state or government ownership suggests that the key decisions are...

Partners Group Holding (SWX:PGHN) has launched a new global special opportunities strategy. The strategy is designed to provide flexible capital solutions in private markets. A newly appointed partner will lead the standalone strategy. The launch responds to liquidity driven opportunities arising from current macro conditions. Partners Group, a global private markets investment manager, is expanding its tool kit with this dedicated special opportunities strategy. For you as an investor, it...

Key Insights Significant control over Siegfried Holding by retail investors implies that the general public has more...

What Alcon’s completed buyback could mean for shareholders Alcon (SWX:ALC) has completed its US$750 million share repurchase program, retiring 9,301,877 shares or about 1.9% of its share capital, a move that directly affects ownership concentration and future dilution. See our latest analysis for Alcon. Despite the completed buyback and earlier interest around Alcon’s upcoming earnings, recent trading has been subdued. The 90 day share price return is 3.37%, while the 1 year total shareholder...

In January 2026, Galderma announced an arbitral tribunal confirmed the termination of its 2014 early-stage neuromodulator R&D partnership with Ipsen, while affirming that commercialization of Dysport/Azzalure, Alluzience, and Relfydess remains unaffected. At the same time, Galderma used major industry meetings such as TOXINS 2026 and IMCAS 2026 to highlight data underscoring the clinical strength and breadth of its neuromodulator portfolio, reinforcing its position in injectable...

There wouldn't be many who think DocMorris AG's ( VTX:DOCM ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...

Why Swiss Re is on watchlists ahead of earnings Swiss Re (SWX:SREN) is drawing increased attention as investors look ahead to its 27 February 2026 earnings release, focusing on the stock’s 4.75% dividend yield and recent trading activity. See our latest analysis for Swiss Re. Recent trading has been choppy, with a 30 day share price return of 7.39% and a 90 day share price return of an 18.66% decline. The 5 year total shareholder return of 111.08% points to momentum that has built over a...

India Energy Week debut puts Sensirion Holding (SWX:SENS) gas metering in focus Sensirion Holding (SWX:SENS) is drawing attention after announcing its first participation at India Energy Week 2026, where it will showcase its thermal mass gas metering technology and newly introduced SGM5304 gas meter module. The event spotlights Sensirion's role in gas metering, with more than 11 million meters installed globally and certification under harmonized standard EN 17526, as investors consider the...

In January 2026, BKW AG held a special call to lower its 2025 EBIT guidance to CHF 540 million–CHF 560 million and introduce a 2026 EBIT range of CHF 650 million–CHF 750 million. This shift in near-term expectations versus a higher 2026 outlook highlights how BKW is recalibrating its earnings profile over the next two years. Next, we will examine how BKW’s reduced 2025 EBIT guidance shapes the company’s investment narrative and risk-reward profile for investors. Trump has pledged to...

Holcim (SWX:HOLN) came into focus after Goldman Sachs shifted its view on the shares from Buy to Neutral, following a strong rally that left the valuation looking full. See our latest analysis for Holcim. The latest CHF78.0 share price comes after a small 1 day share price decline, but that follows an 11.65% 90 day share price return and a very strong 1 year total shareholder return of 73.76%, pointing to momentum that has been building over a longer horizon. That performance also aligns with...

As the European markets show resilience with the STOXX Europe 600 Index ending higher, supported by robust economic data and earnings results, investors are keenly observing opportunities for undervalued stocks amidst mixed performances across major indices. In this context, identifying stocks trading below their intrinsic value can be a strategic move for those looking to capitalize on potential market inefficiencies.

In January 2026, Sandoz confirmed that the European Commission had granted marketing authorization for Ondibta®, a biosimilar insulin glargine pre-filled pen for patients with diabetes aged two and above, matching Lantus® SoloStar® in safety, quality and efficacy. This approval, under Sandoz’s commercialization agreement with Gan & Lee, reinforces its biosimilar footprint in diabetes care and supports broader access to insulin across Europe. We will now examine how this European Commission...

If you are wondering whether Novartis shares offer solid value at today’s price, this article will walk through what the current market is actually paying for the business. Novartis recently closed at $115.10, with returns of 0.5% over 7 days, 4.5% over 30 days, 6.1% year to date, 32.1% over 1 year, 64.6% over 3 years and 77.8% over 5 years. This gives useful context before you weigh up the valuation. Recent attention on Novartis has been shaped by ongoing product pipeline developments and...

Genentech, part of Roche Holding, has expanded its planned investment in a new biomanufacturing facility in North Carolina to US$2b. The site is intended to increase production capacity for weight loss and metabolic condition treatments. The project is expected to support future demand in metabolic diseases and expand Roche's operational footprint in the U.S. Roche Holding (SWX:ROG) is drawing fresh attention as it commits US$2b to new U.S. manufacturing capacity while its shares trade...

In mid-January 2026, analysts from Kepler Capital and Goldman Sachs reiterated Hold views on Swissquote Group Holding while independent Meyka AI issued a positive rating, citing the company’s AI-driven client automation and personalised trading tools alongside resilient 2025 preliminary results. The commentary underscores how Swissquote’s use of AI, combined with robust net income resilience and ongoing client flows into crypto and margin products, is shaping a differentiated growth story...

Logitech International (SWX:LOGN) has introduced its Rally AI Camera and Rally AI Camera Pro, two AI-powered conference cameras. The new products focus on room usage detection, sustainability features, and integration into managed network environments. The launch marks an expansion of Logitech's video collaboration portfolio aimed at enterprise and education customers. For Logitech, known for its peripherals and video collaboration gear, the Rally AI Camera line extends its presence in...

While SIG Group AG ( VTX:SIGN ) might not have the largest market cap around , it led the SWX gainers with a relatively...

As of January 2026, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising by 0.77%, buoyed by strong economic data and earnings results. In this context of mixed performance across major indices like Germany's DAX and France's CAC 40, identifying stocks that may be trading below their estimated value involves looking for companies with solid fundamentals that could benefit from ongoing economic recovery and favorable trade conditions.

As the European market shows resilience with the STOXX Europe 600 Index ending higher, supported by robust economic data and earnings results, investors are increasingly drawn to dividend stocks for their potential to provide steady income in uncertain times. In this context, selecting a good dividend stock involves considering factors like consistent payout history and financial stability, which can offer a buffer against market volatility.

Galderma Group (SWX:GALD) is back in focus after announcing fresh clinical and real world data for its neuromodulators Relfydess and Dysport at the TOXINS 2026 International Conference in Madrid. See our latest analysis for Galderma Group. The fresh neuromodulator data arrives after a softer near term patch for the stock, with a 30 day share price return of 5.53% and a 7 day share price return of a 3.21% decline, even though the 90 day share price return is 12.84% and the 1 year total...